Crimson Publishers-Disabilities

Homocysteine Serum Levels and Methylenetetrahydrofolate (MTHFR) C677T Genotype in Patients with Parkinson's Disease, with and without Levodopa Therapy by Eleonora DŽoljić* and Vladimir Kostić  in Degenerative Intellectual & Developmental Disabilities Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia . Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa -treated and -untreated parkinsonian ("de novo”) patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. https://crimsonpublishe

Anti-Cancer Effects of Zinc (II) Ion in Tumor Formation and Growth, Proliferation, Metastasis and DNA Damage by Ishida T* in Degenerative Intellectual & Developmental Disabilities From the results on antibacterial activities, the killing mechanisms have become clear that bacteriolysis for S. aureus peptidoglycan(PGN) cell wall is due to the inhibition of PGN elongation by the activities of PGN autolysins of amidases, and the other, for E. coli cell wall are due to destruction of outer membrane structure by degrading of lipoprotein at C-, N-terminals, owing to PGN formation inhibition by activities of PGN autolysins of amidase and carboxypeptidase-transpeptidase.  https://crimsonpublishers.com/didd/fulltext/DIDD.000505.php  For more open access journals in Crimson Publishers please click on link: https://crimsonpublishers.com/ For more articles in open access Disabilities journals please click on link: https://crimsonpublishers.com/didd/

Case History of a Novel Treatment Approach for Congenital Cardiomyopathy due to Carnitine Transporter Deficiency by Arun Mukherjee*, Vinod Sharma, Indrajit Neil Roy and Meena Gupta in Degenerative Intellectual & Developmental Disabilities       This is a case study of a novel experimental therapy approach in a rare treatment non-responsive potentially fatal Carnitine Transporter Deficiency Congenital Cardiomyopathy. The child's LVEF was down to about 24% at presentation. As a last resort, we tried out a new multidisciplinary therapy approach. It restored his treatment response and raised his LVEF to a persistent level of 80 to 84% as followed up for last two years. Three of his similarly affected siblings: two brothers and one sister, had earlier succumbed in spite of optimum Levo-Carnitine supplement (the only approved treatment) as provided by one of the most prestigious Medical Institutes of his country https://crimsonpublishers.com/didd/fullte